Insider Buying: Zymeworks Inc. (NYSE:ZYME) Director Acquires 74,125 Shares of Stock

Zymeworks Inc. (NYSE:ZYME - Get Free Report) Director Ecor1 Capital, Llc bought 74,125 shares of the stock in a transaction dated Monday, January 13th. The stock was purchased at an average price of $13.39 per share, with a total value of $992,533.75. Following the acquisition, the director now owns 15,485,203 shares of the company's stock, valued at $207,346,868.17. The trade was a 0.48 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Ecor1 Capital, Llc also recently made the following trade(s):

• On Wednesday, January 15th, Ecor1 Capital, Llc bought 39,029 shares of Zymeworks stock. The shares were purchased at an average cost of $14.01 per share, for a total transaction of $546,796.29.
• On Friday, January 10th, Ecor1 Capital, Llc acquired 204,098 shares of Zymeworks stock. The stock was bought at an average cost of $13.13 per share, for a total transaction of $2,679,806.74.
• On Wednesday, January 8th, Ecor1 Capital, Llc acquired 21,021 shares of Zymeworks stock. The shares were purchased at an average cost of $14.07 per share, with a total value of $295,765.47.
• On Thursday, January 2nd, Ecor1 Capital, Llc purchased 157,880 shares of Zymeworks stock. The shares were purchased at an average cost of $14.78 per share, for a total transaction of $2,333,466.40.
• On Monday, December 30th, Ecor1 Capital, Llc acquired 58,988 shares of Zymeworks stock. The stock was purchased at an average cost of $14.47 per share, with a total value of $853,556.36.
• On Tuesday, December 24th, Ecor1 Capital, Llc acquired 11,958 shares of Zymeworks stock. The shares were acquired at an average cost of $14.12 per share, for a total transaction of $168,846.96.
• On Thursday, December 26th, Ecor1 Capital, Llc purchased 16,692 shares of Zymeworks stock. The stock was acquired at an average cost of $14.38 per share, for a total transaction of $240,030.96.

Zymeworks Trading Up 3.1 %

Shares of ZYME traded up $0.42 during trading hours on Wednesday, reaching $14.04. 383,497 shares of the company's stock traded hands, compared to its average volume of 564,289. Zymeworks Inc. has a 12 month low of $7.97 and a 12 month high of $17.70. The stock has a market cap of $967.05 million, a PE ratio of -9.36 and a beta of 1.10. The firm's 50 day simple moving average is $14.45 and its 200-day simple moving average is $12.55.

Zymeworks (NYSE:ZYME - Get Free Report) last released its quarterly earnings results on Thursday, October 31st. The company reported ($0.39) EPS for the quarter, topping analysts' consensus estimates of ($0.40) by $0.01. The business had revenue of $16.00 million during the quarter, compared to analysts' expectations of $17.90 million. Zymeworks had a negative net margin of 182.75% and a negative return on equity of 23.00%. The business's quarterly revenue was down 3.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.41) EPS. As a group, analysts expect that Zymeworks Inc. will post -1.43 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in ZYME. Charles Schwab Investment Management Inc. lifted its stake in Zymeworks by 0.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 132,798 shares of the company's stock worth $1,667,000 after purchasing an additional 650 shares during the last quarter. Arizona State Retirement System raised its holdings in shares of Zymeworks by 11.1% during the 2nd quarter. Arizona State Retirement System now owns 12,841 shares of the company's stock valued at $109,000 after buying an additional 1,285 shares in the last quarter. FMR LLC lifted its position in Zymeworks by 84.2% in the 3rd quarter. FMR LLC now owns 3,336 shares of the company's stock worth $42,000 after buying an additional 1,525 shares during the last quarter. Stifel Financial Corp boosted its stake in Zymeworks by 2.1% in the third quarter. Stifel Financial Corp now owns 73,654 shares of the company's stock worth $924,000 after buying an additional 1,540 shares in the last quarter. Finally, The Manufacturers Life Insurance Company grew its position in Zymeworks by 13.2% during the second quarter. The Manufacturers Life Insurance Company now owns 22,695 shares of the company's stock valued at $193,000 after acquiring an additional 2,653 shares during the last quarter. Institutional investors own 92.89% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on ZYME. Wells Fargo & Company lifted their price objective on shares of Zymeworks from $12.00 to $14.00 and gave the company an "equal weight" rating in a research note on Thursday, December 19th. Leerink Partners upgraded Zymeworks from a "market perform" rating to an "outperform" rating and lifted their price target for the company from $10.00 to $25.00 in a research report on Thursday, November 7th. JPMorgan Chase & Co. raised Zymeworks from a "neutral" rating to an "overweight" rating and set a $18.00 price objective on the stock in a report on Monday, December 16th. Leerink Partnrs raised Zymeworks from a "hold" rating to a "strong-buy" rating in a report on Thursday, November 7th. Finally, Stifel Nicolaus increased their price target on shares of Zymeworks from $21.00 to $28.00 and gave the stock a "buy" rating in a report on Monday, October 28th. Two equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Zymeworks currently has a consensus rating of "Moderate Buy" and an average price target of $19.17.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.